(Q37893534)

24 August 2017

0 references

HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis (English)

1 reference

24 August 2017

0 references

1 reference

1

Nehmat Houssami

1 reference

24 August 2017

3

Rosemary L Balleine

1 reference

24 August 2017

Petra Macaskill

2

1 reference

24 August 2017

Michael Bilous

series ordinal

4

1 reference

24 August 2017

Mark D Pegram

series ordinal

5

1 reference

24 August 2017

language of work or name

English

0 references

publication date

23 June 2011

1 reference

Breast Cancer Research and Treatment

24 August 2017

1 reference

24 August 2017

129

1 reference

24 August 2017

3

1 reference

24 August 2017

659-674

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-011-1632-x

24 August 2017

0 references

cites work

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

HER2 testing in the UK: consensus from a national consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

HER-2/neu expression in primary and metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

HER2 gene status in primary breast cancers and matched distant metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Stability of HER-2/neu expression over time and at multiple metastatic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

HER-2 gene amplification can be acquired as breast cancer progresses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Concordance between HER-2 and steroid hormone receptor expression between primary breast cancer, sentinel node metastases, and isolated tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Reporting recommendations for tumor marker prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Current perspectives on HER2 testing: a review of national testing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1632-X

10.1007/S10549-011-1632-X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference